What is Tepezza?
Tepezza is an insulin-like growth factor-1 receptor inhibitor (IGF-1R).
Tepezza is used to treat thyroid eye disease (sometimes called Graves Eye Disease).
Thyroid eye disease is an autoimmune disorder in which the immune system attacks tissues around the eyes. Symptoms include dry or watery eyes, eye redness, bulging eyes, vision problems, and difficulty closing the eyes.
Follow all directions on your medicine label and package. Tell each of your healthcare providers about all your medical conditions, allergies, and all medicines you use.
Before taking this medicine
To make sure Tepezza is safe for you, tell your doctor if you have:
diabetes or hyperglycemia (high blood sugar);
Tepezza may harm an unborn baby. Use effective birth control to prevent pregnancy while you are receiving Tepezza and for at least 6 months after your last dose. Tell your doctor if you become pregnant.
It may not be safe to breastfeed while using this medicine. Ask your doctor about any risk.
How is Tepezza given?
Tepezza is given as an infusion into a vein. A healthcare provider will give you this injection.
Tepezza is usually given once every 3 weeks for a total of 8 doses.
This medicine must be given slowly, and the infusion can take 60 to 90 minutes to complete.
Usual Adult Dose for Graves' Ophthalmopathy:
Initial dose: 10 mg/kg intravenously
Maintenance dose: 20 mg/kg intravenously every 3 weeks for 7 additional infusions
Use: Treatment of thyroid eye disease
What happens if I miss a dose?
Call your doctor for instructions if you miss an appointment for your Tepezza.
What happens if I overdose?
Since Tepezza is given by a healthcare professional in a medical setting, an overdose is unlikely to occur.
What should I avoid while receiving Tepezza?
Follow your doctor's instructions about any restrictions on food, beverages, or activity.
Tepezza side effects
Get emergency medical help if you have signs of an allergic reaction to Tepezza: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Some side effects may occur during an injection or within 1.5 hours afterward. Tell your caregiver if you feel hot, anxious, or short of breath, or if you have a headache, muscle pain, or fast heartbeats.
Call your doctor at once if you have:
diarrhea (with or without blood);
bowel movements that occur suddenly;
loss of bowel control;
a feeling of not completely emptying your bowels;
rectal bleeding; or
high blood sugar - increased thirst, increased urination, dry mouth, fruity breath odor.
Common Tepezza side effects may include:
high blood sugar;
dry skin; or
altered sense of taste.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What other drugs will affect Tepezza?
Other drugs may affect Tepezza, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all your current medicines and any medicine you start or stop using.
Does Tepezza cause weight gain?
Weight gain or weight loss is not a known side effect with Tepezza, a prescription medicine used for the treatment of Thyroid Eye Disease (TED). Thyroid eye disease, also known as Graves' ophthalmopathy, commonly affects people with hyperthyroidism (overproduction of thyroid hormones) due to Graves' disease. Studies have shown that treatment of hyperthyroidism with anti-thyroid drug therapy or radioactive iodine therapy frequently leads to weight gain.
Tepezza (teprotumumab) is an inhibitor of insulin-like growth factor-1 receptor (IGF-1R) used to treat Thyroid Eye Disease (TED). It is a monoclonal antibody that blocks IGF-1R activation and signaling. Tepezza decreases eye bulging (proptosis) by decreasing inflammation, preventing muscle and fat tissue remodeling, and preventing tissue expansion behind the eye. Continue reading
In studies with Tepezza (teprotumumab-trbw), some patients began to see less eye bulging and double vision by 6 weeks (after the first 2 treatments). By 24 weeks, 8 out of 10 (80%) of patients saw less eye bulging compared to 10 of 100 (10%) of patients taking a placebo. Continue reading
Tepezza stays in your system approximately 100 days after the last dose. This is calculated by looking at the average half-life of Tepezza which is 20 days. The half-life is the time it takes for 50% of a medicine to be eliminated from the body. Research has shown that it takes 4 to 5 half-lives for a medicine to be fully cleared from the body which calculates out to 80 to 100 days or 11 to 14 weeks for Tepezza. Continue reading
After treatment, Tepezza has been shown in 24-week long clinical studies to reduce the eye bulging, double vision, eye pain, redness and swelling that may occur before treatment with TED. Some patients may have improvement in symptoms as early as 6 weeks. In addition, an improvement in vision (such as reading or watching TV) and in the patient’s appearance was also seen. Continue reading
No, Tepezza is not used for chemotherapy or to treat any form of cancer. Tepezza is used to treat Thyroid Eye Disease, an autoimmune disease. An autoimmune disease is a condition that causes your body's immune system to mistakenly attack healthy cells in your body instead of foreign substances. Continue reading
Tepezza (teprotumumab-trbw) is a prescription medicine used to treat Thyroid Eye Disease (TED). TED often occurs in people living with Graves’ disease (too much thyroid hormone). TED and Graves’ disease are both autoimmune disorders, but are different conditions and are treated differently. Continue reading
More about Tepezza (teprotumumab)
- Side effects
- Drug interactions
- Dosage information
- During pregnancy or Breastfeeding
- Reviews (1)
- Drug images
- Compare alternatives
- Pricing & coupons
- En español
- Drug class: growth hormone receptor blockers
- FDA approval history
Related treatment guides
Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use Tepezza only for the indication prescribed.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Copyright 1996-2022 Cerner Multum, Inc. Version: 1.01.